Entry Point Capital, LLC Rocket Pharmaceuticals, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RCKT
# of Institutions
226Shares Held
96.6MCall Options Held
319KPut Options Held
70.3K-
Rtw Investments, LP New York, NY17.7MShares$174 Million5.21% of portfolio
-
Wellington Management Group LLP Boston, MA14MShares$138 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$64.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$61.1 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.71MShares$46.5 Million0.27% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $746M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...